학술논문

APOE2mitigates disease-related phenotypes in an isogenic hiPSC-based model of Alzheimer’s disease
Document Type
Article
Source
Molecular Psychiatry; October 2021, Vol. 26 Issue: 10 p5715-5732, 18p
Subject
Language
ISSN
13594184; 14765578
Abstract
Genome-wide association studies (GWAS) have identified polymorphism in the Apolipoprotein E gene (APOE) to be the most prominent risk factor for Alzheimer’s disease (AD). Compared to individuals homozygous for the APOE3variant, individuals with the APOE4variant have a significantly elevated risk of AD. On the other hand, longitudinal studies have shown that the presence of the APOE2variant reduces the lifetime risk of developing AD by 40 percent. While there has been significant research that has identified the risk-inducing effects of APOE4, the underlying mechanisms by which APOE2influences AD onset and progression have not been extensively explored. In this study, we utilize an isogenic human induced pluripotent stem cell (hiPSC)-based system to demonstrate that conversion of APOE3to APOE2greatly reduced the production of amyloid-beta (Aβ) peptides in hiPSC-derived neural cultures. Mechanistically, analysis of pure populations of neurons and astrocytes derived from these neural cultures revealed that mitigating effects of APOE2are mediated by cell autonomous and non-autonomous effects. In particular, we demonstrated the reduction in Aβ is potentially driven by a mechanism related to non-amyloidogenic processing of amyloid precursor protein (APP), suggesting a gain of the protective function of the APOE2variant. Together, this study provides insights into the risk-modifying effects associated with the APOE2allele and establishes a platform to probe the mechanisms by which APOE2enhances neuroprotection against AD.